Bibliography — irritable bowel syndrome

Every paper cited in this condition's wiki pages and literature artifacts, grouped by topic. 378 records, every identifier resolved live from PubMed E-utilities on 2026-09-02; none written from memory. A paper cited by several pages is filed under the first topic that cites it; the cited by field lists every page.

Format: Author, et al. Title. Journal. Year;vol(issue):pages. PMID: nnnnnnnn — cited by: page.md, page2.md

Diagnostic criteria, classification and subtyping

31 records.

• Arif TB, et al. Global prevalence and risk factors of irritable bowel syndrome from 2006 to 2024 using the Rome III and IV criteria: a meta-analysis. Eur J Gastroenterol Hepatol. 2025;37(12):1314-1325. PMID 40359286 — cited by: diagnosis-and-rome-criteria.md, epidemiology-and-burden.md
• Begtrup LM, et al. A positive diagnostic strategy is noninferior to a strategy of exclusion for patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2013;11(8):956-62.e1. PMID 23357491 — cited by: diagnosis-and-rome-criteria.md
• Black CJ, et al. Latent class analysis does not support the existence of Rome IV functional bowel disorders as discrete entities. Neurogastroenterol Motil. 2022;34(11):e14391. PMID 35531932 — cited by: diagnosis-and-rome-criteria.md, overlap-with-functional-dyspepsia.md, overview.md
• Black CJ, et al. Novel Symptom Subgroups in Individuals With Irritable Bowel Syndrome Predict Disease Impact and Burden. Clin Gastroenterol Hepatol. 2024;22(2):386-396.e10. PMID 36858142 — cited by: diagnosis-and-rome-criteria.md, epidemiology-and-burden.md, quality-of-life-and-stigma.md
• Black CJ, et al. Novel Irritable Bowel Syndrome Subgroups Are Reproducible in the Global Adult Population. Clin Gastroenterol Hepatol. 2025;23(6):1039-1048.e7. PMID 38876193 — cited by: diagnosis-and-rome-criteria.md, epidemiology-and-burden.md, quality-of-life-and-stigma.md
• Drossman DA, et al. The functional gastrointestinal disorders and the Rome II process. Gut. 1999;45 Suppl 2(Suppl 2):II1-5. PMID 10457038 — cited by: diagnosis-and-rome-criteria.md
• Drossman DA, et al. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. Gastroenterology. 2016. PMID 27144617 — cited by: diagnosis-and-rome-criteria.md, overview.md
• Drossman DA, et al. Disorders of Gut-Brain Interaction and the Rome V Process. Gastroenterology. 2026;170(6):1083-1098. PMID 42031435 — cited by: diagnosis-and-rome-criteria.md, guidelines.md, overview.md
• Engel T, et al. Physician-Patient Discordance in Bristol Stool Scale Classification and Overall IBS Burden Assessment. Am J Gastroenterol. 2026. PMID 42289094 — cited by: diagnosis-and-rome-criteria.md
• Engsbro AL, et al. A positive diagnostic strategy is safe and saves endoscopies in patients with irritable bowel syndrome: A five-year follow-up of a randomized controlled trial. Neurogastroenterol Motil. 2021;33(3):e14004. PMID 33029843 — cited by: diagnosis-and-rome-criteria.md, red-flags-and-safety-concerns.md
• Ersryd A, et al. Subtyping the irritable bowel syndrome by predominant bowel habit: Rome II versus Rome III. Aliment Pharmacol Ther. 2007;26(6):953-61. PMID 17767480 — cited by: diagnosis-and-rome-criteria.md
• Ford AC, et al. Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10414):1773-1785. PMID 37858323 — cited by: clinical-trials-landscape.md, diagnosis-and-rome-criteria.md, guidelines.md, gut-brain-neuromodulators.md, overview.md, placebo-response-and-trial-design.md, psychological-therapy.md, red-flags-and-safety-concerns.md
• Goodoory VC, et al. Assessing Diagnostic Performance of Modifications to the Rome IV Criteria for Irritable Bowel Syndrome. Clin Gastroenterol Hepatol. 2024;22(9):1942-1943. PMID 38423348 — cited by: diagnosis-and-rome-criteria.md
• Goodoory VC, et al. Validating Simple Modifications to the Rome IV Criteria for the Diagnosis of Irritable Bowel Syndrome in Secondary Care. Aliment Pharmacol Ther. 2025;61(2):354-362. PMID 39466700 — cited by: diagnosis-and-rome-criteria.md
• Goodoory VC, et al. Novel Symptom Subgroups in Patients With Irritable Bowel Syndrome Are Associated With Healthcare Utilisation in Secondary and Tertiary Care. Aliment Pharmacol Ther. 2026;63(11):1474-1486. PMID 41714311 — cited by: diagnosis-and-rome-criteria.md
• Hreinsson JP, et al. Factor Analysis of the Rome IV Criteria for Major Disorders of Gut-Brain Interaction (DGBI) Globally and Across Geographical, Sex, and Age Groups. Gastroenterology. 2023;164(7):1211-1222. PMID 36889555 — cited by: diagnosis-and-rome-criteria.md
• Jellema P, et al. Systematic review: accuracy of symptom-based criteria for diagnosis of irritable bowel syndrome in primary care. Aliment Pharmacol Ther. 2009;30(7):695-706. PMID 19575763 — cited by: diagnosis-and-rome-criteria.md
• Khasawneh M, et al. Stability of Classification Systems for Irritable Bowel Syndrome. Aliment Pharmacol Ther. 2026;63(8):1132-1139. PMID 41447016 — cited by: diagnosis-and-rome-criteria.md, epidemiology-and-burden.md, overview.md
• Kruis W, et al. A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease. Gastroenterology. 1984;87(1):1-7. PMID 6724251 — cited by: diagnosis-and-rome-criteria.md
• Longstreth GF, et al. Functional bowel disorders. Gastroenterology. 2006;130(5):1480-91. PMID 16678561 — cited by: diagnosis-and-rome-criteria.md
• Manning AP, et al. Towards positive diagnosis of the irritable bowel. Br Med J. 1978;2(6138):653-4. PMID 698649 — cited by: diagnosis-and-rome-criteria.md
• Nordin E, et al. Modest Conformity Between Self-Reporting of Bristol Stool Form and Fecal Consistency Measured by Stool Water Content in Irritable Bowel Syndrome and a FODMAP and Gluten Trial. Am J Gastroenterol. 2022;117(10):1668-1674. PMID 36087104 — cited by: diagnosis-and-rome-criteria.md
• Palsson OS, et al. Rome IV Diagnostic Questionnaires and Tables for Investigators and Clinicians. Gastroenterology. 2016. PMID 27144634 — cited by: diagnosis-and-rome-criteria.md
• Palsson OS, et al. Prevalence of Rome IV Functional Bowel Disorders Among Adults in the United States, Canada, and the United Kingdom. Gastroenterology. 2020;158(5):1262-1273.e3. PMID 31917991 — cited by: diagnosis-and-rome-criteria.md, epidemiology-and-burden.md, overview.md, quality-of-life-and-stigma.md
• Pimentel M, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1):22-32. PMID 21208106 — cited by: diagnosis-and-rome-criteria.md, overview.md, rifaximin-and-the-sibo-question.md
• Sood R, et al. Systematic review with meta-analysis: the accuracy of diagnosing irritable bowel syndrome with symptoms, biomarkers and/or psychological markers. Aliment Pharmacol Ther. 2015;42(5):491-503. PMID 26076071 — cited by: brain-gut-axis-and-visceral-hypersensitivity.md, diagnosis-and-rome-criteria.md, microbiome.md, overview.md, post-infectious-ibs.md
• Sperber AD, et al. Rome V global epidemiology and validation survey: prevalence of disorders of gut-brain interaction and comparison with the Rome IV global epidemiology study. Gut. 2026. PMID 42613194 — cited by: diagnosis-and-rome-criteria.md, epidemiology-and-burden.md, overlap-with-functional-dyspepsia.md, overview.md
• Staller K, et al. The Rome V criteria for the diagnosis of irritable bowel syndrome in secondary care: a diagnostic accuracy study. Lancet Gastroenterol Hepatol. 2026;11(9):812-820. PMID 42392123 — cited by: clinical-trials-landscape.md, diagnosis-and-rome-criteria.md, guidelines.md, overview.md
• Talley NJ, et al. Diagnostic value of the Manning criteria in irritable bowel syndrome. Gut. 1990;31(1):77-81. PMID 2318433 — cited by: diagnosis-and-rome-criteria.md
• Thompson WG, et al. Functional bowel disorders and functional abdominal pain. Gut. 1999;45 Suppl 2(Suppl 2):II43-7. PMID 10457044 — cited by: diagnosis-and-rome-criteria.md
• Whitehead WE, et al. Validation of symptom-based diagnostic criteria for irritable bowel syndrome: a critical review. Am J Gastroenterol. 2010;105(4):814-20; quiz 813, 821. PMID 20179688 — cited by: diagnosis-and-rome-criteria.md

Epidemiology, natural history and economic burden

18 records.

• Almario CV, et al. Prevalence and Burden of Illness of Rome IV Irritable Bowel Syndrome in the United States: Results From a Nationwide Cross-Sectional Study. Gastroenterology. 2023;165(6):1475-1487. PMID 37595647 — cited by: epidemiology-and-burden.md
• Ballena-Caicedo J, et al. Global Prevalence of Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Analysis. Gastroenterology Res. 2025;18(6):308-321. PMID 41488823 — cited by: epidemiology-and-burden.md
• Black CJ, et al. Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Rev Gastroenterol Hepatol. 2020;17(8):473-486. PMID 32296140 — cited by: epidemiology-and-burden.md
• Buono JL, et al. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population. J Manag Care Spec Pharm. 2017;23(4):453-460. PMID 28345443 — cited by: epidemiology-and-burden.md
• Flacco ME, et al. Costs of irritable bowel syndrome in European countries with universal healthcare coverage: a meta-analysis. Eur Rev Med Pharmacol Sci. 2019;23(7):2986-3000. PMID 31002149 — cited by: epidemiology-and-burden.md
• Gasperi M, et al. Exploring Sex Differences in Irritable Bowel Syndrome Prevalence, Environmental Risk, and Comorbidities: A Population-Based Cohort Study of Veterans. Clin Transl Gastroenterol. 2026;17(3):e00967. PMID 41489281 — cited by: brain-gut-axis-and-visceral-hypersensitivity.md, epidemiology-and-burden.md
• Gutiérrez-Torres DS, et al. The Time-Dependent Association Between Irritable Bowel Syndrome and All-Cause and Cause-Specific Mortality in the NIH-AARP Cohort Study. Am J Gastroenterol. 2025; advance online publication. PMID 41518229 — cited by: epidemiology-and-burden.md
• Krogsgaard LR, et al. The epidemiology of irritable bowel syndrome: Symptom development over a 3-year period in Denmark. A prospective, population-based cohort study. Neurogastroenterol Motil. 2017;29(4). PMID 27865035 — cited by: epidemiology-and-burden.md
• Lovell RM, et al. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712-721.e4. PMID 22426087 — cited by: epidemiology-and-burden.md
• Nellesen D, et al. A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation. J Manag Care Pharm. 2013;19(9):755-64. PMID 24156644 — cited by: epidemiology-and-burden.md
• Neo KML, et al. Cost-of-Illness of Irritable Bowel Syndrome: A Systematic Review. J Gastroenterol Hepatol. 2026;41(9):2557-2570. PMID 42538760 — cited by: epidemiology-and-burden.md, overview.md, quality-of-life-and-stigma.md
• Oka P, et al. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(10):908-917. PMID 32702295 — cited by: epidemiology-and-burden.md, overview.md
• Shin A, et al. The Prevalence, Humanistic Burden, and Health Care Impact of Irritable Bowel Syndrome Among United States Veterans. Clin Gastroenterol Hepatol. 2023;21(4):1061-1069.e1. PMID 35964894 — cited by: epidemiology-and-burden.md
• Sperber AD, et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology. 2021;160(1):99-114.e3. PMID 32294476 — cited by: epidemiology-and-burden.md
• Staller K, et al. Diagnostic yield of endoscopy in irritable bowel syndrome: A nationwide prevalence study 1987-2016. Eur J Intern Med. 2021;94:85-92. PMID 34420846 — cited by: differential-diagnosis-and-exclusion.md, epidemiology-and-burden.md, red-flags-and-safety-concerns.md
• Tack J, et al. Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries. BMC Gastroenterol. 2019;19(1):69. PMID 31064345 — cited by: epidemiology-and-burden.md
• Takeoka A, et al. Prevalence of Irritable Bowel Syndrome in Japan, China, and South Korea: An International Cross-sectional Study. J Neurogastroenterol Motil. 2023;29(2):229-237. PMID 37019867 — cited by: epidemiology-and-burden.md
• Yadav YS, et al. Review article: irritable bowel syndrome: natural history, bowel habit stability and overlap with other gastrointestinal disorders. Aliment Pharmacol Ther. 2021;54 Suppl 1:S24-S32. PMID 34927758 — cited by: epidemiology-and-burden.md

Differential diagnosis, investigation and test yield

21 records.

• Asghar Z, et al. Diagnostic Yield of Colonoscopy in Patients With Symptoms Compatible With Rome IV Functional Bowel Disorders. Clin Gastroenterol Hepatol. 2022;20(2):334-341.e3. PMID 32882424 — cited by: diarrhoea-predominant-pharmacotherapy.md, differential-diagnosis-and-exclusion.md, red-flags-and-safety-concerns.md
• Black CJ, et al. Rational investigations in irritable bowel syndrome. Frontline Gastroenterol. 2020;11(2):140-147. PMID 32133113 — cited by: differential-diagnosis-and-exclusion.md, guidelines.md, red-flags-and-safety-concerns.md, rifaximin-and-the-sibo-question.md
• Camilleri M, et al. When and What to Test for Diarrhea: Focus on Stool Testing. Am J Gastroenterol. 2025;120(4):778-784. PMID 39480027 — cited by: differential-diagnosis-and-exclusion.md, red-flags-and-safety-concerns.md
• Cash BD, et al. The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review. Am J Gastroenterol. 2002;97(11):2812-9. PMID 12425553 — cited by: differential-diagnosis-and-exclusion.md
• Dajti E, et al. Systematic review with meta-analysis: Diagnostic performance of faecal calprotectin in distinguishing inflammatory bowel disease from irritable bowel syndrome in adults. Aliment Pharmacol Ther. 2023;58(11-12):1120-1131. PMID 37823411 — cited by: differential-diagnosis-and-exclusion.md
• Dilmaghani S, et al. Meta-Analysis: Efficacy and Safety of Sequestrants for Bile Acid Diarrhoea. Aliment Pharmacol Ther. 2025;62(11-12):1054-1065. PMID 41090475 — cited by: diarrhoea-predominant-pharmacotherapy.md, differential-diagnosis-and-exclusion.md, guidelines.md, red-flags-and-safety-concerns.md
• Ford AC, et al. Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis. Arch Intern Med. 2009;169(7):651-8. PMID 19364994 — cited by: differential-diagnosis-and-exclusion.md
• Hanevik K, et al. Irritable bowel syndrome and chronic fatigue 6 years after giardia infection: a controlled prospective cohort study. Clin Infect Dis. 2014;59(10):1394-400. PMID 25115874 — cited by: differential-diagnosis-and-exclusion.md, post-infectious-ibs.md, red-flags-and-safety-concerns.md
• Irvine AJ, et al. Screening for Celiac Disease in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-analysis. Am J Gastroenterol. 2017;112(1):65-76. PMID 27753436 — cited by: differential-diagnosis-and-exclusion.md
• Leeds JS, et al. Some patients with irritable bowel syndrome may have exocrine pancreatic insufficiency. Clin Gastroenterol Hepatol. 2010;8(5):433-8. PMID 19835990 — cited by: differential-diagnosis-and-exclusion.md, red-flags-and-safety-concerns.md
• Maconi G, et al. The impact of symptoms, irritable bowel syndrome pattern and diagnostic investigations on the diagnostic delay of Crohn's disease: A prospective study. Dig Liver Dis. 2015;47(8):646-51. PMID 26004215 — cited by: differential-diagnosis-and-exclusion.md, red-flags-and-safety-concerns.md
• Miko S, et al. Postinfectious Syndromes and Long-Term Sequelae after Giardia Infections. Emerg Infect Dis. 2025;31(14):45-52. PMID 41570191 — cited by: differential-diagnosis-and-exclusion.md, post-infectious-ibs.md
• Olmos JI, et al. Exocrine Pancreatic Insufficiency is Undiagnosed in Some Patients with Diarrhea-Predominant Irritable Bowel Syndrome Using the Rome IV Criteria. Dig Dis Sci. 2022;67(12):5666-5675. PMID 35704255 — cited by: differential-diagnosis-and-exclusion.md, red-flags-and-safety-concerns.md
• Pop A, et al. Self-Perceived Lactose Intolerance Versus Confirmed Lactose Intolerance in Irritable Bowel Syndrome: A Systematic Review. J Gastrointestin Liver Dis. 2024. PMID 39255349 — cited by: dietary-therapy.md, differential-diagnosis-and-exclusion.md, red-flags-and-safety-concerns.md
• Shiha MG, et al. Global Prevalence of Celiac Disease in Patients With Rome III and Rome IV Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2025;120(12):2776-2787. PMID 40493044 — cited by: diarrhoea-predominant-pharmacotherapy.md, differential-diagnosis-and-exclusion.md, red-flags-and-safety-concerns.md
• Shiha MG, et al. Global prevalence of self-reported non-coeliac gluten and wheat sensitivity: a systematic review and meta-analysis. Gut. 2025. PMID 41151790 — cited by: dietary-therapy.md, differential-diagnosis-and-exclusion.md
• Shin A, et al. Research Communication: An Observational Cohort Study on Risk of Ovarian Cancer in Women with Irritable Bowel Syndrome. Aliment Pharmacol Ther. 2025;62(9):944-947. PMID 41081454 — cited by: differential-diagnosis-and-exclusion.md, quality-of-life-and-stigma.md, red-flags-and-safety-concerns.md
• Slattery SA, et al. Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther. 2015;42(1):3-11. PMID 25913530 — cited by: diarrhoea-predominant-pharmacotherapy.md, differential-diagnosis-and-exclusion.md, guidelines.md, red-flags-and-safety-concerns.md
• Valentin N, et al. Biomarkers for bile acid diarrhoea in functional bowel disorder with diarrhoea: a systematic review and meta-analysis. Gut. 2016;65(12):1951-1959. PMID 26347530 — cited by: differential-diagnosis-and-exclusion.md, guidelines.md
• Wedlake L, et al. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2009;30(7):707-17. PMID 19570102 — cited by: differential-diagnosis-and-exclusion.md
• Wu J, et al. Diagnostic yield of colonoscopy for organic disease in irritable bowel syndrome and its risk factors: A meta-analysis. Neurogastroenterol Motil. 2023;35(2):e14481. PMID 36168183 — cited by: differential-diagnosis-and-exclusion.md, red-flags-and-safety-concerns.md

Pathophysiology: gut-brain axis, visceral hypersensitivity, genetics

25 records.

• Agrawal A, et al. Bloating and distention in irritable bowel syndrome: the role of visceral sensation. Gastroenterology. 2008;134(7):1882-9. PMID 18455167 — cited by: brain-gut-axis-and-visceral-hypersensitivity.md
• Bayrer JR, et al. Gut enterochromaffin cells drive visceral pain and anxiety. Nature. 2023;616(7955):137-142. PMID 36949192 — cited by: brain-gut-axis-and-visceral-hypersensitivity.md
• Burns GL, et al. Serological and faecal markers of irritable bowel syndrome: a systematic review and meta-analysis. EBioMedicine. 2026;126:106198. PMID 41793943 — cited by: brain-gut-axis-and-visceral-hypersensitivity.md, microbiome.md
• Ding H, et al. The Association Between Childhood Maltreatment and Adult Intestinal Disorders: A Three-Level Meta-Analysis. Trauma Violence Abuse. 2026:15248380261460029. PMID 42312593 — cited by: brain-gut-axis-and-visceral-hypersensitivity.md
• Dothel G, et al. Nerve fiber outgrowth is increased in the intestinal mucosa of patients with irritable bowel syndrome. Gastroenterology. 2015;148(5):1002-1011.e4. PMID 25655556 — cited by: brain-gut-axis-and-visceral-hypersensitivity.md
• Díaz-Muñoz C, et al. Genetic dissection of stool frequency implicates vitamin B1 metabolism and other actionable pathways in the modulation of gut motility. Gut. 2026;75(8):1480-1490. PMID 41558814 — cited by: brain-gut-axis-and-visceral-hypersensitivity.md
• Eijsbouts C, et al. Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders. Nat Genet. 2021;53(11):1543-1552. PMID 34741163 — cited by: brain-gut-axis-and-visceral-hypersensitivity.md, gut-brain-neuromodulators.md, overview.md, post-infectious-ibs.md
• Fukudo S, et al. Stress and visceral pain: focusing on irritable bowel syndrome. Pain. 2013;154 Suppl 1:S63-S70. PMID 24021863 — cited by: brain-gut-axis-and-visceral-hypersensitivity.md
• Gong W, et al. Role of the Gut-Brain Axis in the Shared Genetic Etiology Between Gastrointestinal Tract Diseases and Psychiatric Disorders: A Genome-Wide Pleiotropic Analysis. JAMA Psychiatry. 2023;80(4):360-370. PMID 36753304 — cited by: brain-gut-axis-and-visceral-hypersensitivity.md
• Holliday EG, et al. Genome-wide association study identifies two novel genomic regions in irritable bowel syndrome. Am J Gastroenterol. 2014;109(5):770-2. PMID 24797007 — cited by: brain-gut-axis-and-visceral-hypersensitivity.md
• Huang W, et al. Unraveling the genetic susceptibility of irritable bowel syndrome: integrative genome-wide analyses in 845 492 individuals: a diagnostic study. Int J Surg. 2025;111(1):210-220. PMID 39166955 — cited by: brain-gut-axis-and-visceral-hypersensitivity.md
• Josefsson A, et al. Visceral sensitivity remains stable over time in patients with irritable bowel syndrome, but with individual fluctuations. Neurogastroenterol Motil. 2019;31(7):e13603. PMID 31012215 — cited by: brain-gut-axis-and-visceral-hypersensitivity.md
• Josefsson A, et al. Type of Rectal Barostat Protocol Affects Classification of Hypersensitivity and Prediction of Symptom Severity in Irritable Bowel Syndrome. J Neurogastroenterol Motil. 2022;28(4):630-641. PMID 36250370 — cited by: brain-gut-axis-and-visceral-hypersensitivity.md
• Koloski NA, et al. The brain--gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study. Gut. 2012;61(9):1284-90. PMID 22234979 — cited by: brain-gut-axis-and-visceral-hypersensitivity.md, post-infectious-ibs.md
• Kuiken SD, et al. Relationship between symptoms and hypersensitivity to rectal distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2005;22(2):157-64. PMID 16011674 — cited by: brain-gut-axis-and-visceral-hypersensitivity.md
• Low EXS, et al. Parental, Perinatal, and Childhood Risk Factors for Development of Irritable Bowel Syndrome: A Systematic Review. J Neurogastroenterol Motil. 2020;26(4):437-446. PMID 32989183 — cited by: brain-gut-axis-and-visceral-hypersensitivity.md
• Ludidi S, et al. Rectal hypersensitivity as hallmark for irritable bowel syndrome: defining the optimal cutoff. Neurogastroenterol Motil. 2012;24(8):729-33, e345-6. PMID 22591192 — cited by: brain-gut-axis-and-visceral-hypersensitivity.md, overview.md
• Meerveld BG, et al. Mechanisms of Stress-induced Visceral Pain. J Neurogastroenterol Motil. 2018;24(1):7-18. PMID 29291604 — cited by: brain-gut-axis-and-visceral-hypersensitivity.md
• Nasser Y, et al. Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol Hepatol. 2026. PMID 42462748 — cited by: brain-gut-axis-and-visceral-hypersensitivity.md, overlap-with-functional-dyspepsia.md, overview.md, post-infectious-ibs.md
• Nozu T, et al. Corticotropin-releasing factor receptor type 1 and type 2 interaction in irritable bowel syndrome. J Gastroenterol. 2015;50(8):819-30. PMID 25962711 — cited by: brain-gut-axis-and-visceral-hypersensitivity.md
• Pia F, et al. Dose-Dependent Effect of the Histamine 1 Receptor Antagonist Ebastine in Patients With Non-Constipated Irritable Bowel Syndrome. Neurogastroenterol Motil. 2026;38(1):e70242. PMID 41603723 — cited by: brain-gut-axis-and-visceral-hypersensitivity.md
• Sjölund J, et al. Quality of Life and Bidirectional Gut-Brain Interactions in Irritable Bowel Syndrome From Adolescence to Adulthood. Clin Gastroenterol Hepatol. 2024;22(4):858-866.e6. PMID 37802270 — cited by: brain-gut-axis-and-visceral-hypersensitivity.md
• Vanuytsel T, et al. Understanding neuroimmune interactions in disorders of gut-brain interaction: from functional to immune-mediated disorders. Gut. 2023;72(4):787-798. PMID 36657961 — cited by: brain-gut-axis-and-visceral-hypersensitivity.md, overlap-with-functional-dyspepsia.md
• Venkataraman A, et al. A cellular basis for heightened gut sensitivity in females. Science. 2025;390(6779):1285-1291. PMID 41411420 — cited by: brain-gut-axis-and-visceral-hypersensitivity.md
• Zhao M, et al. Functional changes of default mode network and structural alterations of gray matter in patients with irritable bowel syndrome: a meta-analysis of whole-brain studies. Front Neurosci. 2023;17:1236069. PMID 37942144 — cited by: brain-gut-axis-and-visceral-hypersensitivity.md

Microbiome, probiotics and faecal microbiota transplantation

35 records.

• Ahmed T, et al. The Interplay Between Immunological Status and Gut Microbial Dysbiosis in the Development of the Symptoms of Irritable Bowel Syndrome: A Systematic Review with Meta-Analysis. Dig Dis Sci. 2026;71(2):376-410. PMID 40903688 — cited by: microbiome.md
• Brenner DM, et al. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol. 2009;104(4):1033-49; quiz 1050. PMID 19277023 — cited by: microbiome.md
• Charbonneau D, et al. Fecal excretion of Bifidobacterium infantis 35624 and changes in fecal microbiota after eight weeks of oral supplementation with encapsulated probiotic. Gut Microbes. 2013;4(3):201-11. PMID 23549409 — cited by: microbiome.md
• Cox SR, et al. Effects of Low FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory Bowel Disease in a Randomized Trial. Gastroenterology. 2020;158(1):176-188.e7. PMID 31586453 — cited by: microbiome.md
• El-Salhy M, et al. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut. 2020;69(5):859-867. PMID 31852769 — cited by: microbiome.md, overview.md
• Ford AC, et al. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther. 2018;48(10):1044-1060. PMID 30294792 — cited by: microbiome.md, rifaximin-and-the-sibo-question.md
• Ghoshal U, et al. Irritable Bowel Syndrome, Particularly the Constipation-Predominant Form, Involves an Increase in Methanobrevibacter smithii, Which Is Associated with Higher Methane Production. Gut Liver. 2016;10(6):932-938. PMID 27458176 — cited by: microbiome.md
• Goodoory VC, et al. Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis. Gastroenterology. 2023;165(5):1206-1218. PMID 37541528 — cited by: microbiome.md, overview.md
• Gottlieb K, et al. Review article: inhibition of methanogenic archaea by statins as a targeted management strategy for constipation and related disorders. Aliment Pharmacol Ther. 2016;43(2):197-212. PMID 26559904 — cited by: microbiome.md
• Halkjær SI, et al. Fecal microbiota transplantation for the treatment of irritable bowel syndrome: A systematic review and meta-analysis. World J Gastroenterol. 2023;29(20):3185-3202. PMID 37346153 — cited by: microbiome.md
• Hubert S, et al. Development of a Modified-Release Formulation of Lovastatin Targeted to Intestinal Methanogens Implicated in Irritable Bowel Syndrome With Constipation. J Pharm Sci. 2018;107(2):662-671. PMID 28989013 — cited by: microbiome.md
• Ju X, et al. Changes in Fecal Short-Chain Fatty Acids in IBS Patients and Effects of Different Interventions: A Systematic Review and Meta-Analysis. Nutrients. 2024;16(11). PMID 38892659 — cited by: microbiome.md
• Kim G, et al. Methanobrevibacter smithii is the predominant methanogen in patients with constipation-predominant IBS and methane on breath. Dig Dis Sci. 2012;57(12):3213-8. PMID 22573345 — cited by: microbiome.md
• Lahtinen P, et al. Randomised clinical trial: faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome. Aliment Pharmacol Ther. 2020;51(12):1321-1331. PMID 32343000 — cited by: microbiome.md, overview.md
• Li X, et al. Meta-analysis of gut microbiota alterations in patients with irritable bowel syndrome. Front Microbiol. 2024;15:1492349. PMID 39777150 — cited by: microbiome.md
• Li Y, et al. Fecal bacteria can predict the efficacy of rifaximin in patients with diarrhea-predominant irritable bowel syndrome. Pharmacol Res. 2020;159:104936. PMID 32470562 — cited by: microbiome.md, rifaximin-and-the-sibo-question.md
• Lo SW, et al. Clinical efficacy and safety of faecal microbiota transplantation in the treatment of irritable bowel syndrome: a systematic review, meta-analysis and trial sequential analysis. Eur J Med Res. 2024;29(1):464. PMID 39289768 — cited by: microbiome.md
• Luo M, et al. Alterations in short-chain fatty acids and serotonin in irritable bowel syndrome: a systematic review and meta-analysis. BMC Gastroenterol. 2021;21(1):14. PMID 33407171 — cited by: microbiome.md
• Maslennikov R, et al. Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome. J Clin Med. 2026;15(3). PMID 41682832 — cited by: microbiome.md
• Muskal SM, et al. Lovastatin lactone may improve irritable bowel syndrome with constipation (IBS-C) by inhibiting enzymes in the archaeal methanogenesis pathway. F1000Res. 2016;5:606. PMID 27347377 — cited by: microbiome.md
• Ng QX, et al. What Has Longitudinal 'Omics' Studies Taught Us about Irritable Bowel Syndrome? A Systematic Review. Metabolites. 2023;13(4). PMID 37110143 — cited by: microbiome.md
• O'Mahony L, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128(3):541-51. PMID 15765388 — cited by: microbiome.md
• Pittayanon R, et al. Gut Microbiota in Patients With Irritable Bowel Syndrome-A Systematic Review. Gastroenterology. 2019;157(1):97-108. PMID 30940523 — cited by: microbiome.md, overview.md
• Ringel-Kulka T, et al. Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Benefit of the Probiotic Bifidobacterium infantis 35624 in Non-Patients With Symptoms of Abdominal Discomfort and Bloating. Am J Gastroenterol. 2017;112(1):145-151. PMID 27845337 — cited by: microbiome.md
• So D, et al. Effects of a low FODMAP diet on the colonic microbiome in irritable bowel syndrome: a systematic review with meta-analysis. Am J Clin Nutr. 2022;116(4):943-952. PMID 35728042 — cited by: microbiome.md
• Staudacher HM, et al. Gut microbiota associations with diet in irritable bowel syndrome and the effect of low FODMAP diet and probiotics. Clin Nutr. 2021;40(4):1861-1870. PMID 33183883 — cited by: microbiome.md
• Sun Q, et al. Alterations in fecal short-chain fatty acids in patients with irritable bowel syndrome: A systematic review and meta-analysis. Medicine (Baltimore). 2019;98(7):e14513. PMID 30762787 — cited by: microbiome.md
• Sundin J, et al. Evidence of altered mucosa-associated and fecal microbiota composition in patients with Irritable Bowel Syndrome. Sci Rep. 2020;10(1):593. PMID 31953505 — cited by: microbiome.md
• Talamantes S, et al. Intestinal Methanogen Overgrowth (IMO) Is Associated with Delayed Small Bowel and Colonic Transit Time (TT) on the Wireless Motility Capsule (WMC). Dig Dis Sci. 2024;69(9):3361-3368. PMID 39068378 — cited by: microbiome.md, rifaximin-and-the-sibo-question.md
• Villanueva-Millan MJ, et al. Methanogens and Hydrogen Sulfide Producing Bacteria Guide Distinct Gut Microbe Profiles and Irritable Bowel Syndrome Subtypes. Am J Gastroenterol. 2022;117(12):2055-2066. PMID 36114762 — cited by: microbiome.md
• Villanueva-Millan MJ, et al. Hydrogen Sulfide Producers Drive a Diarrhea-Like Phenotype and a Methane Producer Drives a Constipation-Like Phenotype in Animal Models. Dig Dis Sci. 2024;69(2):426-436. PMID 38060167 — cited by: microbiome.md
• Whorwell PJ, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006;101(7):1581-90. PMID 16863564 — cited by: microbiome.md
• Wu Y, et al. The Efficacy of Probiotics, Prebiotics, Synbiotics, and Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis. Nutrients. 2024;16(13). PMID 38999862 — cited by: microbiome.md
• Yau YK, et al. Randomised clinical trial: Faecal microbiota transplantation for irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther. 2023;58(8):795-804. PMID 37667968 — cited by: microbiome.md, overview.md
• Yuan F, et al. Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis. Curr Med Res Opin. 2017;33(7):1191-1197. PMID 28166427 — cited by: microbiome.md

Post-infectious IBS

20 records.

• Barros LL, et al. Anti-CdtB and anti-vinculin antibodies to diagnose irritable bowel syndrome in inflammatory bowel disease patients. BMC Gastroenterol. 2024;24(1):448. PMID 39627697 — cited by: post-infectious-ibs.md
• Dunlop SP, et al. Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome. Aliment Pharmacol Ther. 2003;18(1):77-84. PMID 12848628 — cited by: post-infectious-ibs.md
• Ford AC, et al. Prevalence of uninvestigated dyspepsia 8 years after a large waterborne outbreak of bacterial dysentery: a cohort study. Gastroenterology. 2010;138(5):1727-36; quiz e12. PMID 20117111 — cited by: overlap-with-functional-dyspepsia.md, post-infectious-ibs.md
• Klem F, et al. Prevalence, Risk Factors, and Outcomes of Irritable Bowel Syndrome After Infectious Enteritis: A Systematic Review and Meta-analysis. Gastroenterology. 2017;152(5):1042-1054.e1. PMID 28069350 — cited by: post-infectious-ibs.md, red-flags-and-safety-concerns.md
• Marshall JK, et al. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology. 2006;131(2):445-50; quiz 660. PMID 16890598 — cited by: post-infectious-ibs.md
• Marshall JK, et al. Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut. 2010;59(5):605-11. PMID 20427395 — cited by: overlap-with-functional-dyspepsia.md, post-infectious-ibs.md
• Morales W, et al. Second-Generation Biomarker Testing for Irritable Bowel Syndrome Using Plasma Anti-CdtB and Anti-Vinculin Levels. Dig Dis Sci. 2019;64(11):3115-3121. PMID 31152332 — cited by: post-infectious-ibs.md
• Pimentel M, et al. Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects. PLoS One. 2015;10(5):e0126438. PMID 25970536 — cited by: post-infectious-ibs.md
• Porcari S, et al. Prevalence of irritable bowel syndrome and functional dyspepsia after acute gastroenteritis: systematic review and meta-analysis. Gut. 2024;73(9):1431-1440. PMID 39013599 — cited by: overlap-with-functional-dyspepsia.md, overview.md, post-infectious-ibs.md
• Rezaie A, et al. Assessment of Anti-vinculin and Anti-cytolethal Distending Toxin B Antibodies in Subtypes of Irritable Bowel Syndrome. Dig Dis Sci. 2017;62(6):1480-1485. PMID 28451914 — cited by: post-infectious-ibs.md
• Schmulson M, et al. Clinical experience with the use of anti-CdtB and anti-vinculin antibodies in patients with diarrhea in Mexico. Rev Gastroenterol Mex. 2016;81(4):236-239. PMID 27681080 — cited by: post-infectious-ibs.md
• Schwille-Kiuntke J, et al. Systematic review with meta-analysis: post-infectious irritable bowel syndrome after travellers' diarrhoea. Aliment Pharmacol Ther. 2015;41(11):1029-37. PMID 25871571 — cited by: post-infectious-ibs.md
• Svendsen AT, et al. Systematic review with meta-analyses: does the pathogen matter in post-infectious irritable bowel syndrome?. Scand J Gastroenterol. 2019;54(5):546-562. PMID 31112663 — cited by: post-infectious-ibs.md
• Talley NJ, et al. Circulating Anti-cytolethal Distending Toxin B and Anti-vinculin Antibodies as Biomarkers in Community and Healthcare Populations With Functional Dyspepsia and Irritable Bowel Syndrome. Clin Transl Gastroenterol. 2019;10(7):e00064. PMID 31356481 — cited by: post-infectious-ibs.md
• Thabane M, et al. Systematic review and meta-analysis: The incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther. 2007;26(4):535-44. PMID 17661757 — cited by: post-infectious-ibs.md
• Thabane M, et al. Development and validation of a risk score for post-infectious irritable bowel syndrome. Am J Gastroenterol. 2009;104(9):2267-74. PMID 19568228 — cited by: clinical-trials-landscape.md, post-infectious-ibs.md
• Thabane M, et al. An outbreak of acute bacterial gastroenteritis is associated with an increased incidence of irritable bowel syndrome in children. Am J Gastroenterol. 2010;105(4):933-9. PMID 20179687 — cited by: post-infectious-ibs.md
• Vasapolli R, et al. Gut microbiota profiles and the role of anti-CdtB and anti-vinculin antibodies in patients with functional gastrointestinal disorders (FGID). Eur J Clin Invest. 2021;51(12):e13666. PMID 34390492 — cited by: post-infectious-ibs.md
• Villani AC, et al. Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology. 2010;138(4):1502-13. PMID 20044998 — cited by: post-infectious-ibs.md
• Zanini B, et al. Incidence of post-infectious irritable bowel syndrome and functional intestinal disorders following a water-borne viral gastroenteritis outbreak. Am J Gastroenterol. 2012;107(6):891-9. PMID 22525306 — cited by: post-infectious-ibs.md

Dietary therapy

24 records.

• Altobelli E, et al. Low-FODMAP Diet Improves Irritable Bowel Syndrome Symptoms: A Meta-Analysis. Nutrients. 2017;9(9). PMID 28846594 — cited by: dietary-therapy.md
• Atkins M, et al. Assessment and management of disorders of gut-brain interaction in patients with eating disorders. J Eat Disord. 2023;11(1):20. PMID 36782302 — cited by: dietary-therapy.md, red-flags-and-safety-concerns.md
• Black CJ, et al. Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(2):117-131. PMID 31859183 — cited by: antispasmodics-and-peppermint.md, dietary-therapy.md, gut-brain-neuromodulators.md, overview.md, red-flags-and-safety-concerns.md
• Böhn L, et al. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. Gastroenterology. 2015;149(6):1399-1407.e2. PMID 26255043 — cited by: dietary-therapy.md
• Carbone F, et al. Diet or medication in primary care patients with IBS: the DOMINO study - a randomised trial supported by the Belgian Health Care Knowledge Centre (KCE Trials Programme) and the Rome Foundation Research Institute. Gut. 2022;71(11):2226-2232. PMID 35483886 — cited by: clinical-trials-landscape.md, dietary-therapy.md, overview.md
• Cuffe MS, et al. Efficacy of dietary interventions in irritable bowel syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2025;10(6):520-536. PMID 40258374 — cited by: dietary-therapy.md, overview.md
• Di Rosa C, et al. DOMINO trial post hoc analysis: evaluation of the diet effects on symptoms in IBS subtypes. Ther Adv Gastroenterol. 2024;17:17562848241255296. PMID 39086991 — cited by: clinical-trials-landscape.md, dietary-therapy.md
• Gao J, et al. Low Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols Diet Improves Colonic Barrier Function and Mast Cell Activation in Patients With Diarrhea-Predominant Irritable Bowel Syndrome: A Mechanistic Trial. Gastroenterology. 2026;170(1):132-147. PMID 40749856 — cited by: dietary-therapy.md, overlap-with-functional-dyspepsia.md
• Goyal O, et al. Prevalence and predictors of nonceliac wheat sensitivity in refractory irritable bowel syndrome and functional dyspepsia: results from a randomized double-blind placebo-controlled study. Eur J Gastroenterol Hepatol. 2025;37(11):1238-1248. PMID 41025571 — cited by: dietary-therapy.md
• Halmos EP, et al. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014;146(1):67-75.e5. PMID 24076059 — cited by: dietary-therapy.md
• Halmos EP, et al. Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut. 2015;64(1):93-100. PMID 25016597 — cited by: dietary-therapy.md, red-flags-and-safety-concerns.md
• McKenzie YA, et al. British Dietetic Association systematic review of systematic reviews and evidence-based practice guidelines for the use of probiotics in the management of irritable bowel syndrome in adults (2016 update). J Hum Nutr Diet. 2016;29(5):576-92. PMID 27265510 — cited by: dietary-therapy.md, guidelines.md
• McKenzie YA, et al. British Dietetic Association systematic review and evidence-based practice guidelines for the dietary management of irritable bowel syndrome in adults (2016 update). J Hum Nutr Diet. 2016;29(5):549-75. PMID 27272325 — cited by: dietary-therapy.md, guidelines.md
• Nybacka S, et al. A low FODMAP diet plus traditional dietary advice versus a low-carbohydrate diet versus pharmacological treatment in irritable bowel syndrome (CARIBS): a single-centre, single-blind, randomised controlled trial. Lancet Gastroenterol Hepatol. 2024;9(6):507-520. PMID 38643782 — cited by: antispasmodics-and-peppermint.md, clinical-trials-landscape.md, constipation-predominant-pharmacotherapy.md, diarrhoea-predominant-pharmacotherapy.md, dietary-therapy.md, guidelines.md, overview.md
• O'Keeffe M, et al. Long-term impact of the low-FODMAP diet on gastrointestinal symptoms, dietary intake, patient acceptability, and healthcare utilization in irritable bowel syndrome. Neurogastroenterol Motil. 2018;30(1). PMID 28707437 — cited by: dietary-therapy.md, red-flags-and-safety-concerns.md
• Routhiaux K, et al. Involvement of Eosinophil-Driven Intestinal Immune Activation in Different Irritable Bowel Syndrome Subtypes and in the Response to a FODMAP Lowering Diet: A Post Hoc Analysis of the Randomized Controlled DOMINO Trial. Gastroenterology. 2026;170(4):818-820. PMID 41670574 — cited by: clinical-trials-landscape.md, dietary-therapy.md
• Saadati S, et al. Effects of a gluten challenge in patients with irritable bowel syndrome: a randomized single-blind controlled clinical trial. Sci Rep. 2022;12(1):4960. PMID 35322144 — cited by: dietary-therapy.md
• Scarlata K, et al. A Call to Action: Unraveling the Nuance of Adapted Eating Behaviors in Individuals With Gastrointestinal Conditions. Clin Gastroenterol Hepatol. 2025;23(6):893-901.e2. PMID 39681226 — cited by: dietary-therapy.md, red-flags-and-safety-concerns.md
• Staudacher HM, et al. Fiber Supplementation in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Gastroenterology. 2026. PMID 42600900 — cited by: dietary-therapy.md
• Tack C, et al. A study on the utility of inflammatory biomarkers in primary care irritable bowel syndrome: a sub analysis of the DOMINO randomized trial. BMC Gastroenterol. 2025;26(1):69. PMID 41436948 — cited by: clinical-trials-landscape.md, dietary-therapy.md
• Tunali V, et al. A Multicenter Randomized Controlled Trial of Microbiome-Based Artificial Intelligence-Assisted Personalized Diet vs Low-Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols Diet: A Novel Approach for the Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2024;119(9):1901-1912. PMID 38717025 — cited by: dietary-therapy.md
• Tunali V, et al. Long-term microbiome and clinical effects of a microbiome-guided personalized diet versus low-FODMAP diet in irritable bowel syndrome: A 12-month follow-up randomized controlled trial. Gut Microbes. 2026;18(1):2719125. PMID 42623122 — cited by: dietary-therapy.md
• Van den Houte K, et al. Efficacy and Findings of a Blinded Randomized Reintroduction Phase for the Low FODMAP Diet in Irritable Bowel Syndrome. Gastroenterology. 2024;167(2):333-342. PMID 38401741 — cited by: dietary-therapy.md, placebo-response-and-trial-design.md, red-flags-and-safety-concerns.md
• Wilson B, et al. β-Galactooligosaccharide in Conjunction With Low FODMAP Diet Improves Irritable Bowel Syndrome Symptoms but Reduces Fecal Bifidobacteria. Am J Gastroenterol. 2020;115(6):906-915. PMID 32433273 — cited by: dietary-therapy.md, red-flags-and-safety-concerns.md

Antispasmodics and peppermint oil

20 records.

• Alammar N, et al. The impact of peppermint oil on the irritable bowel syndrome: a meta-analysis of the pooled clinical data. BMC Complement Altern Med. 2019;19(1):21. PMID 30654773 — cited by: antispasmodics-and-peppermint.md
• Amato A, et al. Effects of menthol on circular smooth muscle of human colon: analysis of the mechanism of action. Eur J Pharmacol. 2014;740:295-301. PMID 25046841 — cited by: antispasmodics-and-peppermint.md
• Chumpitazi BP, et al. Review article: the physiological effects and safety of peppermint oil and its efficacy in irritable bowel syndrome and other functional disorders. Aliment Pharmacol Ther. 2018;47(6):738-752. PMID 29372567 — cited by: antispasmodics-and-peppermint.md
• Darvish-Damavandi M, et al. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. World J Gastroenterol. 2010;16(5):547-53. PMID 20128021 — cited by: antispasmodics-and-peppermint.md
• Evangelista S, et al. Otilonium Bromide: A Drug with a Complex Mechanism of Action. Curr Pharm Des. 2018;24(16):1772-1779. PMID 29732965 — cited by: antispasmodics-and-peppermint.md
• Ford AC, et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ. 2008;337:a2313. PMID 19008265 — cited by: antispasmodics-and-peppermint.md
• Hawrelak JA, et al. Western herbal medicines in the treatment of irritable bowel syndrome: A systematic review and meta-analysis. Complement Ther Med. 2020;48:102233. PMID 31987249 — cited by: antispasmodics-and-peppermint.md
• Ingrosso MR, et al. Systematic review and meta-analysis: efficacy of peppermint oil in irritable bowel syndrome. Aliment Pharmacol Ther. 2022;56(6):932-941. PMID 35942669 — cited by: antispasmodics-and-peppermint.md, overview.md
• Khanna R, et al. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. J Clin Gastroenterol. 2014;48(6):505-12. PMID 24100754 — cited by: antispasmodics-and-peppermint.md
• Martínez-Cutillas M, et al. Mechanisms of action of otilonium bromide (OB) in human cultured smooth muscle cells and rat colonic strips. Neurogastroenterol Motil. 2013;25(12):e803-12. PMID 23941257 — cited by: antispasmodics-and-peppermint.md
• Martínez-Vázquez MA, et al. Effect of antispasmodic agents, alone or in combination, in the treatment of Irritable Bowel Syndrome: systematic review and meta-analysis. Rev Gastroenterol Mex. 2012;77(2):82-90. PMID 22672854 — cited by: antispasmodics-and-peppermint.md
• Meyer A, et al. Systematic Review and Meta-Analysis: Plant-Based Therapy for Irritable Bowel Syndrome. Phytother Res. 2026. PMID 42572206 — cited by: antispasmodics-and-peppermint.md
• Pittler MH, et al. Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis. Am J Gastroenterol. 1998;93(7):1131-5. PMID 9672344 — cited by: antispasmodics-and-peppermint.md
• Rexwinkel R, et al. Mebeverine and the Influence of Labeling in Adolescents With Irritable Bowel Syndrome or Functional Abdominal Pain Not Otherwise Specified: A 2 × 2 Randomized, Placebo-Controlled Trial. Gastroenterology. 2025;169(1):94-103. PMID 40074185 — cited by: antispasmodics-and-peppermint.md, gut-brain-neuromodulators.md, overview.md, placebo-response-and-trial-design.md
• Santicioli P, et al. Antimuscarinic, calcium channel blocker and tachykinin NK2 receptor antagonist actions of otilonium bromide in the circular muscle of guinea-pig colon. Naunyn Schmiedebergs Arch Pharmacol. 1999;359(5):420-7. PMID 10498293 — cited by: antispasmodics-and-peppermint.md
• Shulman RJ, et al. Randomised trial: Peppermint oil (menthol) pharmacokinetics in children and effects on gut motility in children with functional abdominal pain. Br J Clin Pharmacol. 2022;88(3):1321-1333. PMID 34528282 — cited by: antispasmodics-and-peppermint.md
• Shulman RJ, et al. Randomized trial: Peppermint oil (menthol) pharmacokinetics in children and effects on gut motility in children with functional abdominal pain: 540 mg vs. 900 mg dose comparison. Br J Clin Pharmacol. 2025;91(9):2711-2724. PMID 40390282 — cited by: antispasmodics-and-peppermint.md
• Vermeijden NK, et al. Peppermint Oil and Sweets in Pediatric Irritable Bowel Syndrome and Functional Abdominal Pain: A Randomized Trial. Clin Gastroenterol Hepatol. 2026;24(8):2286-2296. PMID 41610933 — cited by: antispasmodics-and-peppermint.md
• Weerts ZZRM, et al. Efficacy and Safety of Peppermint Oil in a Randomized, Double-Blind Trial of Patients With Irritable Bowel Syndrome. Gastroenterology. 2020;158(1):123-136. PMID 31470006 — cited by: antispasmodics-and-peppermint.md, overview.md, placebo-response-and-trial-design.md
• Weerts ZZRM, et al. A trial-based economic evaluation of peppermint oil for the treatment of irritable bowel syndrome. United European Gastroenterol J. 2021;9(9):997-1006. PMID 34468079 — cited by: antispasmodics-and-peppermint.md

Pharmacotherapy: IBS with constipation

23 records.

• Al-Juhani A, et al. Tenapanor for Irritable Bowel Syndrome With Constipation (IBS-C): A Systematic Review of Randomized Trials Assessing Food and Drug Administration (FDA) Composite Response, Durability, and Risk-of-Bias (RoB-2). Cureus. 2025;17(9):e93337. PMID 41158898 — cited by: constipation-predominant-pharmacotherapy.md
• Black CJ, et al. Efficacy of Secretagogues in Patients With Irritable Bowel Syndrome With Constipation: Systematic Review and Network Meta-analysis. Gastroenterology. 2018;155(6):1753-1763. PMID 30144426 — cited by: constipation-predominant-pharmacotherapy.md, overview.md
• Brandt LJ, et al. The FDA's decision-making process: isn't it time to temper the principle of protective paternalism?. Am J Gastroenterol. 2008;103(5):1226-7. PMID 18477347 — cited by: constipation-predominant-pharmacotherapy.md
• Brenner DM, et al. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials. Am J Gastroenterol. 2018;113(5):735-745. PMID 29545635 — cited by: constipation-predominant-pharmacotherapy.md
• Brenner DM, et al. Tenapanor Improves Abdominal Symptoms Irrespective of Changes in Complete Spontaneous Bowel Movement Frequency in Adults with Irritable Bowel Syndrome with Constipation. Dig Dis. 2025;43(2):146-157. PMID 39701047 — cited by: constipation-predominant-pharmacotherapy.md
• Busam JA, et al. The Safety of Pharmacotherapy for Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2026;121(3):745-753. PMID 40471839 — cited by: constipation-predominant-pharmacotherapy.md, diarrhoea-predominant-pharmacotherapy.md, gut-brain-neuromodulators.md, placebo-response-and-trial-design.md, red-flags-and-safety-concerns.md, rifaximin-and-the-sibo-question.md
• Chang L, et al. Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2016;44(10):1114-1122. PMID 27669680 — cited by: constipation-predominant-pharmacotherapy.md
• Chang L, et al. AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation. Gastroenterology. 2022;163(1):118-136. PMID 35738724 — cited by: constipation-predominant-pharmacotherapy.md, diarrhoea-predominant-pharmacotherapy.md, guidelines.md, gut-brain-neuromodulators.md, overview.md
• Chapman RW, et al. Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. Am J Gastroenterol. 2013;108(9):1508-15. PMID 23835436 — cited by: constipation-predominant-pharmacotherapy.md
• Chey WD, et al. Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2012;35(5):587-99. PMID 22251419 — cited by: constipation-predominant-pharmacotherapy.md
• Chey WD, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol. 2012;107(11):1702-12. PMID 22986437 — cited by: constipation-predominant-pharmacotherapy.md, red-flags-and-safety-concerns.md, rifaximin-and-the-sibo-question.md
• Chey WD, et al. Randomized Trial of 2 Delayed-Release Formulations of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation. Am J Gastroenterol. 2021;116(2):354-361. PMID 33065589 — cited by: constipation-predominant-pharmacotherapy.md
• Chey WD, et al. Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2). Am J Gastroenterol. 2021;116(6):1294-1303. PMID 33337659 — cited by: constipation-predominant-pharmacotherapy.md, red-flags-and-safety-concerns.md
• Dimidi E, et al. British Dietetic Association Guidelines for the Dietary Management of Chronic Constipation in Adults. J Hum Nutr Diet. 2025;38(5):e70133. PMID 41081513 — cited by: constipation-predominant-pharmacotherapy.md
• Drossman DA, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther. 2009;29(3):329-41. PMID 19006537 — cited by: constipation-predominant-pharmacotherapy.md
• Farmer AD, et al. Linaclotide increases cecal pH, accelerates colonic transit, and increases colonic motility in irritable bowel syndrome with constipation. Neurogastroenterol Motil. 2019;31(2):e13492. PMID 30353623 — cited by: constipation-predominant-pharmacotherapy.md
• Lacy BE, et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2021;116(1):17-44. PMID 33315591 — cited by: constipation-predominant-pharmacotherapy.md, guidelines.md
• Lacy BE, et al. Re-evaluation of the Cardiovascular Safety Profile of Tegaserod: A Review of the Clinical Data. Clin Gastroenterol Hepatol. 2022;20(4):e682-e695. PMID 34048937 — cited by: constipation-predominant-pharmacotherapy.md, red-flags-and-safety-concerns.md
• Lembo AJ, et al. Abdominal Symptom Improvement During Clinical Trials of Tenapanor in Patients With Irritable Bowel Syndrome With Constipation: A Post Hoc Analysis. Am J Gastroenterol. 2024;119(5):937-945. PMID 38294158 — cited by: constipation-predominant-pharmacotherapy.md
• Markham A, et al. Tenapanor: First Approval. Drugs. 2019;79(17):1897-1903. PMID 31677150 — cited by: constipation-predominant-pharmacotherapy.md
• Sayuk GS, et al. Tegaserod: What's Old Is New Again. Clin Gastroenterol Hepatol. 2022;20(10):2175-2184.e19. PMID 35123085 — cited by: constipation-predominant-pharmacotherapy.md
• Vasant DH, et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut. 2021;70(7):1214-1240. PMID 33903147 — cited by: constipation-predominant-pharmacotherapy.md, guidelines.md
• Yiannakou Y, et al. UK clinical experience up to 52 weeks with linaclotide for irritable bowel syndrome with constipation. Therap Adv Gastroenterol. 2018;11:1756284818798791. PMID 30302125 — cited by: constipation-predominant-pharmacotherapy.md

Pharmacotherapy: IBS with diarrhoea

13 records.

• Brenner DM, et al. Efficacy and Safety of Eluxadoline in Patients With Irritable Bowel Syndrome With Diarrhea Who Report Inadequate Symptom Control With Loperamide: RELIEF Phase 4 Study. Am J Gastroenterol. 2019;114(9):1502-1511. PMID 31356229 — cited by: diarrhoea-predominant-pharmacotherapy.md, red-flags-and-safety-concerns.md
• Cash BD, et al. Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea. Am J Gastroenterol. 2017;112(2):365-374. PMID 27922029 — cited by: diarrhoea-predominant-pharmacotherapy.md, red-flags-and-safety-concerns.md
• Fukudo S, et al. Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol. 2014;12(6):953-9.e4. PMID 24315882 — cited by: diarrhoea-predominant-pharmacotherapy.md
• Fukudo S, et al. Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women. Gastroenterology. 2016;150(2):358-66.e8. PMID 26551550 — cited by: diarrhoea-predominant-pharmacotherapy.md, overview.md
• Gawron AJ, et al. Risk of Pancreatitis Following Treatment of Irritable Bowel Syndrome With Eluxadoline. Clin Gastroenterol Hepatol. 2018;16(3):378-384.e2. PMID 28804032 — cited by: diarrhoea-predominant-pharmacotherapy.md, red-flags-and-safety-concerns.md, rifaximin-and-the-sibo-question.md
• Gunn D, et al. Randomised, placebo-controlled trial and meta-analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: The TRITON trial. Aliment Pharmacol Ther. 2023;57(11):1258-1271. PMID 36866724 — cited by: diarrhoea-predominant-pharmacotherapy.md
• Lembo A, et al. AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea. Gastroenterology. 2022;163(1):137-151. PMID 35738725 — cited by: diarrhoea-predominant-pharmacotherapy.md, guidelines.md, gut-brain-neuromodulators.md, rifaximin-and-the-sibo-question.md
• Lembo AJ, et al. Eluxadoline for Irritable Bowel Syndrome with Diarrhea. N Engl J Med. 2016;374(3):242-53. PMID 26789872 — cited by: diarrhoea-predominant-pharmacotherapy.md, overview.md, red-flags-and-safety-concerns.md
• Lewis JH, et al. Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective. Expert Rev Gastroenterol Hepatol. 2010;4(1):13-29. PMID 20136586 — cited by: diarrhoea-predominant-pharmacotherapy.md, red-flags-and-safety-concerns.md
• Lucak SL, et al. Optimizing outcomes with alosetron hydrochloride in severe diarrhea-predominant irritable bowel syndrome. Ther Adv Gastroenterol. 2010;3(3):165-72. PMID 21180598 — cited by: diarrhoea-predominant-pharmacotherapy.md, red-flags-and-safety-concerns.md
• Qi Q, et al. Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials. BMC Gastroenterol. 2018;18(1):5. PMID 29310568 — cited by: diarrhoea-predominant-pharmacotherapy.md
• Rokkas T, et al. Comparative effectiveness of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: a network meta-analysis of randomized controlled studies. Ann Gastroenterol. 2021;34(4):535-546. PMID 34276193 — cited by: diarrhoea-predominant-pharmacotherapy.md, overview.md
• Savarino E, et al. Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility. United European Gastroenterol J. 2022;10(6):556-584. PMID 35695704 — cited by: diarrhoea-predominant-pharmacotherapy.md, guidelines.md

Rifaximin, antibiotics and small intestinal bacterial overgrowth

23 records.

• Aziz I, et al. Small intestinal bacterial overgrowth as a cause for irritable bowel syndrome: guilty or not guilty?. Curr Opin Gastroenterol. 2017;33(3):196-202. PMID 28257307 — cited by: rifaximin-and-the-sibo-question.md
• Damianos JA, et al. Mechanisms and pathophysiology leading to development of small intestinal microbial dysbiosis. Lancet Gastroenterol Hepatol. 2026;11(3):256-266. PMID 41547360 — cited by: rifaximin-and-the-sibo-question.md
• Fodor AA, et al. Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome. Gut Microbes. 2019;10(1):22-33. PMID 29708822 — cited by: rifaximin-and-the-sibo-question.md
• Ford AC, et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2009;7(12):1279-86. PMID 19602448 — cited by: rifaximin-and-the-sibo-question.md
• Iftequar Y, et al. Targeted antibiotic and dietary approaches in managing small intestinal bacterial overgrowth across irritable bowel syndrome subtypes. Intern Emerg Med. 2026. PMID 42310284 — cited by: rifaximin-and-the-sibo-question.md
• Lacy BE, et al. Treatment-Free Interval: A Novel Approach to Assessing Real-World Treatment Effectiveness and Economic Impact Among Patients with Irritable Bowel Syndrome with Diarrhea. Adv Ther. 2024;41(6):2253-2266. PMID 38619720 — cited by: rifaximin-and-the-sibo-question.md
• Lembo A, et al. Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome. Gastroenterology. 2016;151(6):1113-1121. PMID 27528177 — cited by: overview.md, rifaximin-and-the-sibo-question.md
• Lembo A, et al. Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea. Clin Transl Gastroenterol. 2020;11(3):e00144. PMID 32352714 — cited by: rifaximin-and-the-sibo-question.md
• Loh AJC, et al. Reassessing Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: A Comparative Study of Diagnostic Guidelines and Their Clinical Relevance. J Gastroenterol Hepatol. 2026;41(7):2082-2088. PMID 42235989 — cited by: guidelines.md, rifaximin-and-the-sibo-question.md
• Maltz C, et al. Conflicts of Interest in the North American Consensus on Breath Testing. Am J Gastroenterol. 2017;112(12):1892. PMID 29215615 — cited by: rifaximin-and-the-sibo-question.md
• Pimentel M, et al. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98(2):412-9. PMID 12591062 — cited by: rifaximin-and-the-sibo-question.md
• Pimentel M, et al. Antibiotic treatment of constipation-predominant irritable bowel syndrome. Dig Dis Sci. 2014;59(6):1278-85. PMID 24788320 — cited by: rifaximin-and-the-sibo-question.md
• Pimentel M, et al. Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity. Dig Dis Sci. 2017;62(9):2455-2463. PMID 28589238 — cited by: red-flags-and-safety-concerns.md, rifaximin-and-the-sibo-question.md
• Pimentel M, et al. ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. Am J Gastroenterol. 2020;115(2):165-178. PMID 32023228 — cited by: guidelines.md, rifaximin-and-the-sibo-question.md
• Quigley EM, et al. Small intestinal bacterial overgrowth: what it is and what it is not. Curr Opin Gastroenterol. 2014;30(2):141-6. PMID 24406476 — cited by: rifaximin-and-the-sibo-question.md
• Rezaie A, et al. Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. Am J Gastroenterol. 2017;112(5):775-784. PMID 28323273 — cited by: guidelines.md, rifaximin-and-the-sibo-question.md
• Rezaie A, et al. Reply to Satta et al. Am J Gastroenterol. 2018;113(3):440-441. PMID 29535445 — cited by: rifaximin-and-the-sibo-question.md
• Shah A, et al. Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Case-Control Studies. Am J Gastroenterol. 2020;115(2):190-201. PMID 31913194 — cited by: rifaximin-and-the-sibo-question.md
• Shah ED, et al. Value-based Pricing for Rifaximin Increases Access of Patients With Irritable Bowel Syndrome With Diarrhea to Therapy. Clin Gastroenterol Hepatol. 2019;17(13):2687-2695.e11. PMID 30831219 — cited by: rifaximin-and-the-sibo-question.md
• Shah ED, et al. Comparing Costs and Outcomes of Treatments for Irritable Bowel Syndrome With Diarrhea: Cost-Benefit Analysis. Clin Gastroenterol Hepatol. 2022;20(1):136-144.e31. PMID 33010413 — cited by: rifaximin-and-the-sibo-question.md
• Su T, et al. Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth. J Gastroenterol. 2018;53(1):27-36. PMID 28770351 — cited by: rifaximin-and-the-sibo-question.md
• Takakura W, et al. Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome - An Update. Front Psychiatry. 2020;11:664. PMID 32754068 — cited by: rifaximin-and-the-sibo-question.md
• Usai-Satta P, et al. The North American Consensus on Breath Testing: The Controversial Diagnostic Role of Lactulose in SIBO. Am J Gastroenterol. 2018;113(3):440. PMID 29535443 — cited by: rifaximin-and-the-sibo-question.md

Gut-brain neuromodulators

17 records.

• Brennan BP, et al. Duloxetine in the treatment of irritable bowel syndrome: an open-label pilot study. Hum Psychopharmacol. 2009;24(5):423-8. PMID 19548294 — cited by: gut-brain-neuromodulators.md
• Bundeff AW, et al. Selective serotonin reuptake inhibitors for the treatment of irritable bowel syndrome. Ann Pharmacother. 2014;48(6):777-84. PMID 24651166 — cited by: gut-brain-neuromodulators.md
• Drossman DA, et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology. 2003;125(1):19-31. PMID 12851867 — cited by: gut-brain-neuromodulators.md
• Ford AC, et al. Effect of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Analysis. Am J Gastroenterol. 2019;114(1):21-39. PMID 30177784 — cited by: guidelines.md, gut-brain-neuromodulators.md, psychological-therapy.md
• Friedrich M, et al. Effects of antidepressants in patients with irritable bowel syndrome and comorbid depression. Clin Ther. 2010;32(7):1221-33. PMID 20678672 — cited by: gut-brain-neuromodulators.md
• Houghton LA, et al. Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut. 2007;56(9):1218-25. PMID 17446306 — cited by: gut-brain-neuromodulators.md
• Houghton LA, et al. Clinical Trial: Study to Investigate the Efficacy and Safety of the Alpha-2-Delta Ligand PD-217,014 in Patients With Irritable Bowel Syndrome. Aliment Pharmacol Ther. 2025;61(5):803-813. PMID 39812493 — cited by: gut-brain-neuromodulators.md
• Kaplan A, et al. An open-label trial of duloxetine in patients with irritable bowel syndrome and comorbid generalized anxiety disorder. Int J Psychiatry Clin Pract. 2014;18(1):11-5. PMID 23980534 — cited by: gut-brain-neuromodulators.md
• Kerckhove N, et al. Ethosuximide and Irritable Bowel Syndrome-Related Abdominal Pain: A Randomized Clinical Trial. JAMA Netw Open. 2026;9(1):e2551368. PMID 41505133 — cited by: gut-brain-neuromodulators.md
• Khalilian A, et al. A randomized, double-blind, placebo-controlled study to assess efficacy of mirtazapine for the treatment of diarrhea predominant irritable bowel syndrome. Biopsychosoc Med. 2021;15(1):3. PMID 33536043 — cited by: gut-brain-neuromodulators.md
• Khasawneh M, et al. Efficacy of gut-brain neuromodulators in irritable bowel syndrome: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2025;10(6):537-549. PMID 40258375 — cited by: guidelines.md, gut-brain-neuromodulators.md, overview.md
• Lewis-Fernández R, et al. An Open-Label Pilot Study of Duloxetine in Patients With Irritable Bowel Syndrome and Comorbid Major Depressive Disorder. J Clin Psychopharmacol. 2016;36(6):710-715. PMID 27755218 — cited by: gut-brain-neuromodulators.md
• Prodan R, et al. Mirtazapine for the treatment of irritable bowel syndrome: A systematic review. World J Methodol. 2026;16(1):107908. PMID 41809155 — cited by: gut-brain-neuromodulators.md
• Rahimi R, et al. Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis. World J Gastroenterol. 2009;15(13):1548-53. PMID 19340896 — cited by: gut-brain-neuromodulators.md
• Weinland SR, et al. Cognitive factors affect treatment response to medical and psychological treatments in functional bowel disorders. Am J Gastroenterol. 2010;105(6):1397-406. PMID 20087332 — cited by: gut-brain-neuromodulators.md
• Wright-Hughes A, et al. Low-dose titrated amitriptyline as second-line treatment for adults with irritable bowel syndrome in primary care: the ATLANTIS RCT. Health Technol Assess. 2024;28(66):1-161. PMID 39397570 — cited by: gut-brain-neuromodulators.md, psychological-therapy.md, quality-of-life-and-stigma.md, red-flags-and-safety-concerns.md
• Wright-Hughes A, et al. Predictors of response to low-dose amitriptyline for irritable bowel syndrome and efficacy and tolerability according to subtype: post hoc analyses from the ATLANTIS trial. Gut. 2025;74(5):728-739. PMID 39863398 — cited by: gut-brain-neuromodulators.md

Psychological and brain-gut behavioural therapy

18 records.

• Berry SK, et al. A Randomized Parallel-group Study of Digital Gut-directed Hypnotherapy vs Muscle Relaxation for Irritable Bowel Syndrome. Clin Gastroenterol Hepatol. 2023;21(12):3152-3159.e2. PMID 37391055 — cited by: clinical-trials-landscape.md, psychological-therapy.md
• Black CJ, et al. Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis. Gut. 2020;69(8):1441-1451. PMID 32276950 — cited by: placebo-response-and-trial-design.md, psychological-therapy.md
• Devenney J, et al. Clinical trial: predictive factors for response to gut-directed hypnotherapy for refractory irritable bowel syndrome, a post hoc analysis. Aliment Pharmacol Ther. 2024;59(2):269-277. PMID 37927144 — cited by: psychological-therapy.md
• Everitt HA, et al. Assessing telephone-delivered cognitive-behavioural therapy (CBT) and web-delivered CBT versus treatment as usual in irritable bowel syndrome (ACTIB): a multicentre randomised trial. Gut. 2019;68(9):1613-1623. PMID 30971419 — cited by: clinical-trials-landscape.md, overview.md, psychological-therapy.md
• Gaylord SA, et al. Mindfulness Training Has Long-term Therapeutic Benefits in Women with Irritable Bowel Syndrome. Mindfulness (N Y). 2024;15(9):2233-2244. PMID 42453561 — cited by: psychological-therapy.md
• Goodoory VC, et al. Effect of Brain-Gut Behavioral Treatments on Abdominal Pain in Irritable Bowel Syndrome: Systematic Review and Network Meta-Analysis. Gastroenterology. 2024;167(5):934-943.e5. PMID 38777133 — cited by: psychological-therapy.md
• Häuser W, et al. Gut-directed hypnosis and hypnotherapy for irritable bowel syndrome: a mini-review. Front Psychol. 2024;15:1389911. PMID 38887623 — cited by: psychological-therapy.md
• Kim H, et al. Internet-Delivered Cognitive Behavioral Therapy in Patients With Irritable Bowel Syndrome: Systematic Review and Meta-Analysis. J Med Internet Res. 2022;24(6):e35260. PMID 35687389 — cited by: psychological-therapy.md
• Lövdahl J, et al. Randomised clinical trial: individual versus group hypnotherapy for irritable bowel syndrome. Aliment Pharmacol Ther. 2022;55(12):1501-1511. PMID 35505463 — cited by: psychological-therapy.md
• Lövdahl J, et al. Nurse-Administered Gut-Directed Hypnotherapy for Irritable Bowel Syndrome: A Two-Year Follow-Up Study. United European Gastroenterol J. 2025;13(7):1307-1317. PMID 40491242 — cited by: overview.md, psychological-therapy.md
• Maas Genannt Bermpohl F, et al. Efficacy of mindfulness- and acceptance-based cognitive-behavioral therapies for bodily distress in adults: a meta-analysis. Front Psychiatry. 2023;14:1160908. PMID 37151971 — cited by: psychological-therapy.md
• Nunan D, et al. Physical activity for treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2022;6(6):CD011497. PMID 35766861 — cited by: psychological-therapy.md
• Taghvaeinia A, et al. Comparison of the Effect of Dialectical Behavior Therapy, Acceptance and Commitment Therapy mindfulness-based Stress Reduction on Irritable Bowel Syndrome Symptoms, Quality of Life, Anxiety and Depression: A Pilot Randomized Controlled Trial. Psychiatr Q. 2024;95(1):53-68. PMID 37976011 — cited by: psychological-therapy.md
• Tao QF, et al. Face-to-Face Versus Digital, Telephone-Delivered, and Self-Help Cognitive Behavioral Therapy for Irritable Bowel Syndrome: Systematic Review and Bayesian Indirect Treatment Comparison Meta-Analysis. J Med Internet Res. 2026;28:e75833. PMID 41505702 — cited by: psychological-therapy.md
• Thakur ER, et al. Efficacy of behavioural therapies for irritable bowel syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2025;10(12):1075-1088. PMID 41077057 — cited by: overview.md, placebo-response-and-trial-design.md, psychological-therapy.md
• Wallén H, et al. Internet-Delivered Exposure-Based Cognitive Behavior Therapy for Irritable Bowel Syndrome: A Clinical Effectiveness Study. Am J Gastroenterol. 2025;120(4):856-863. PMID 39194012 — cited by: psychological-therapy.md
• Zernicke KA, et al. Mindfulness-based stress reduction for the treatment of irritable bowel syndrome symptoms: a randomized wait-list controlled trial. Int J Behav Med. 2013;20(3):385-96. PMID 22618308 — cited by: psychological-therapy.md
• Zhou C, et al. Exercise therapy of patients with irritable bowel syndrome: A systematic review of randomized controlled trials. Neurogastroenterol Motil. 2019;31(2):e13461. PMID 30232834 — cited by: psychological-therapy.md

Placebo, nocebo, endpoints and trial design

13 records.

• Ballou S, et al. Psychological Predictors of Response to Open-Label Versus Double-Blind Placebo in a Randomized Controlled Trial in Irritable Bowel Syndrome. Psychosom Med. 2022;84(6):738-746. PMID 35412513 — cited by: placebo-response-and-trial-design.md
• Barberio B, et al. Placebo Response Rates in Trials of Licensed Drugs for Irritable Bowel Syndrome With Constipation or Diarrhea: Meta-analysis. Clin Gastroenterol Hepatol. 2022;20(5):e923-e944. PMID 34425274 — cited by: placebo-response-and-trial-design.md
• Bosman M, et al. The placebo response rate in pharmacological trials in patients with irritable bowel syndrome: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(6):459-473. PMID 33765447 — cited by: overview.md, placebo-response-and-trial-design.md
• Ford AC, et al. Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. Aliment Pharmacol Ther. 2010;32(2):144-58. PMID 20412064 — cited by: overview.md, placebo-response-and-trial-design.md
• Francis CY, et al. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997;11(2):395-402. PMID 9146781 — cited by: placebo-response-and-trial-design.md
• Kaptchuk TJ, et al. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ. 2008;336(7651):999-1003. PMID 18390493 — cited by: overview.md, placebo-response-and-trial-design.md, quality-of-life-and-stigma.md
• Kaptchuk TJ, et al. Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS One. 2010;5(12):e15591. PMID 21203519 — cited by: placebo-response-and-trial-design.md
• Lacy BE, et al. Responders vs clinical response: a critical analysis of data from linaclotide phase 3 clinical trials in IBS-C. Neurogastroenterol Motil. 2014;26(3):326-33. PMID 24382134 — cited by: placebo-response-and-trial-design.md
• Lembo A, et al. Open-label placebo vs double-blind placebo for irritable bowel syndrome: a randomized clinical trial. Pain. 2021;162(9):2428-2435. PMID 33605656 — cited by: overview.md, placebo-response-and-trial-design.md
• Li R, et al. Nocebo response intensity and influencing factors in the randomized clinical trials of irritable bowel syndrome: A systematic review and meta-analysis. Front Med (Lausanne). 2022;9:1018713. PMID 36606047 — cited by: placebo-response-and-trial-design.md
• Nurko S, et al. Effect of Open-label Placebo on Children and Adolescents With Functional Abdominal Pain or Irritable Bowel Syndrome: A Randomized Clinical Trial. JAMA Pediatr. 2022;176(4):349-356. PMID 35099543 — cited by: placebo-response-and-trial-design.md
• Vollert J, et al. Genotypes of Pain and Analgesia in a Randomized Trial of Irritable Bowel Syndrome. Front Psychiatry. 2022;13:842030. PMID 35401282 — cited by: placebo-response-and-trial-design.md
• Wang RS, et al. Genomic Effects Associated With Response to Placebo Treatment in a Randomized Trial of Irritable Bowel Syndrome. Front Pain Res (Lausanne). 2021;2:775386. PMID 35295415 — cited by: placebo-response-and-trial-design.md

Overlap with functional dyspepsia and other conditions

18 records.

• Andreev DN, et al. [Prevalence of combination of functional dyspepsia and irritable bowel syndrome: a meta-analysis of studies using the Rome III-IV Criteria]. Ter Arkh. 2022;94(9):1099-1108. PMID 36286762 — cited by: overlap-with-functional-dyspepsia.md, overview.md
• Barberio B, et al. Overlap of Rome IV Irritable Bowel Syndrome and Functional Dyspepsia and Effect on Natural History: A Longitudinal Follow-Up Study. Clin Gastroenterol Hepatol. 2022;20(2):e89-e101. PMID 33839276 — cited by: overlap-with-functional-dyspepsia.md, overview.md
• Choi YJ, et al. Overlap between irritable bowel syndrome and functional dyspepsia including subtype analyses. J Gastroenterol Hepatol. 2017;32(9):1553-1561. PMID 28160607 — cited by: overlap-with-functional-dyspepsia.md
• Enck P, et al. Functional dyspepsia. Nat Rev Dis Primers. 2017;3:17081. PMID 29099093 — cited by: overlap-with-functional-dyspepsia.md
• Futagami S, et al. Systematic review with meta-analysis: post-infectious functional dyspepsia. Aliment Pharmacol Ther. 2015;41(2):177-88. PMID 25348873 — cited by: overlap-with-functional-dyspepsia.md
• Gwee KA, et al. Asia-Pacific guidelines for managing functional dyspepsia overlapping with other gastrointestinal symptoms. J Gastroenterol Hepatol. 2023;38(2):197-209. PMID 36321167 — cited by: guidelines.md, overlap-with-functional-dyspepsia.md
• Holtmann G, et al. Pathophysiology of Functional Gastrointestinal Disorders: A Holistic Overview. Dig Dis. 2017;35 Suppl 1:5-13. PMID 29421808 — cited by: overlap-with-functional-dyspepsia.md
• Jones MP, et al. Overlap of heartburn, functional dyspepsia, and irritable bowel syndrome in a population sample: Prevalence, temporal stability, and associated comorbidities. Neurogastroenterol Motil. 2022;34(9):e14349. PMID 35293084 — cited by: overlap-with-functional-dyspepsia.md
• Lovell RM, et al. Prevalence of gastro-esophageal reflux-type symptoms in individuals with irritable bowel syndrome in the community: a meta-analysis. Am J Gastroenterol. 2012;107(12):1793-801; quiz 1802. PMID 23032982 — cited by: overlap-with-functional-dyspepsia.md
• Nakov R, et al. Prevalence of Irritable Bowel Syndrome, Functional Dyspepsia and their Overlap in Bulgaria: a Population-Based Study. J Gastrointestin Liver Dis. 2020;29(3):329-338. PMID 32919417 — cited by: overlap-with-functional-dyspepsia.md
• Pasricha PJ, et al. Functional Dyspepsia. N Engl J Med. 2026;394(2):166-176. PMID 41499733 — cited by: overlap-with-functional-dyspepsia.md
• Schol J, et al. The Six-food Elimination Diet Improves Symptoms of Functional Dyspepsia. Clin Gastroenterol Hepatol. 2025. PMID 41354185 — cited by: overlap-with-functional-dyspepsia.md
• Schol J, et al. The effect of corticotropin-release hormone on duodenal permeability and immune activation in healthy volunteers in a double-blind placebo-controlled study. Am J Physiol Gastrointest Liver Physiol. 2025;328(5):G457-G464. PMID 40167262 — cited by: overlap-with-functional-dyspepsia.md
• Talley NJ, et al. Why are disorders of gut-brain interaction (DGBI) often food-related? Duodenal eosinophils and mast cells, small intestinal bacteria, food allergy and altered food intake in functional dyspepsia and the irritable bowel syndrome: a new paradigm. J Gastroenterol. 2025;60(10):1211-1220. PMID 40586878 — cited by: overlap-with-functional-dyspepsia.md
• Vanheel H, et al. Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia. Gut. 2014;63(2):262-71. PMID 23474421 — cited by: overlap-with-functional-dyspepsia.md
• Vanheel H, et al. Duodenal acidification induces gastric relaxation and alters epithelial barrier function by a mast cell independent mechanism. Sci Rep. 2020;10(1):17448. PMID 33060783 — cited by: overlap-with-functional-dyspepsia.md
• Wang XJ, et al. Comorbid extra-intestinal central sensitization conditions worsen irritable bowel syndrome in primary care patients. Neurogastroenterol Motil. 2023;35(4):e14546. PMID 36807964 — cited by: overlap-with-functional-dyspepsia.md
• von Wulffen M, et al. Overlap of Irritable Bowel Syndrome and Functional Dyspepsia in the Clinical Setting: Prevalence and Risk Factors. Dig Dis Sci. 2019;64(2):480-486. PMID 30368683 — cited by: overlap-with-functional-dyspepsia.md

Quality of life, work impact and stigma

25 records.

• Andreyev HJN, et al. Clinical and cost effectiveness of nurse led-structured management of diarrhoea predominant irritable bowel syndrome in primary care (Lincolnshire POACHER study); a randomised control trial. BMC Prim Care. 2026;27(1):187. PMID 41922986 — cited by: quality-of-life-and-stigma.md
• Bontempo AC, et al. Ignored, dismissed, and minimized: Understanding the harmful consequences of invalidation in health care-A systematic meta-synthesis of qualitative research. Psychol Bull. 2025;151(4):399-427. PMID 40310228 — cited by: quality-of-life-and-stigma.md, red-flags-and-safety-concerns.md
• Björkman I, et al. The gendered impact of Irritable Bowel Syndrome: a qualitative study of patients' experiences. J Adv Nurs. 2014;70(6):1334-43. PMID 24224642 — cited by: patient-voice/sources.md, patient-voice/themes.md
• Frändemark Å, et al. Maintaining work life under threat of symptoms: a grounded theory study of work life experiences in persons with Irritable Bowel Syndrome. BMC Gastroenterol. 2022;22(1):73. PMID 35183112 — cited by: patient-voice/sources.md, patient-voice/themes.md
• Brenner DM, et al. Improved work productivity and health-related quality of life in patients with irritable bowel syndrome with diarrhea receiving eluxadoline following inadequate response to loperamide. J Manag Care Spec Pharm. 2021;27(4):469-477. PMID 33769858 — cited by: quality-of-life-and-stigma.md
• Buono JL, et al. Impact of linaclotide treatment on work productivity and activity impairment in adults with irritable bowel syndrome with constipation: results from 2 randomized, double-blind, placebo-controlled phase 3 trials. Am Health Drug Benefits. 2014;7(5):289-97. PMID 25237424 — cited by: quality-of-life-and-stigma.md
• Buono JL, et al. Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea. Health Qual Life Outcomes. 2017;15(1):35. PMID 28196491 — cited by: quality-of-life-and-stigma.md
• Drossman DA, et al. A focus group assessment of patient perspectives on irritable bowel syndrome and illness severity. Dig Dis Sci. 2009;54(7):1532-41. PMID 19337833 — cited by: quality-of-life-and-stigma.md
• Dhaliwal SK, Hunt RH. Doctor-patient interaction for irritable bowel syndrome in primary care: a systematic perspective. Eur J Gastroenterol Hepatol. 2004;16(11):1161-6. PMID 15489576 — cited by: patient-voice/sources.md, patient-voice/themes.md
• El-Serag HB, et al. Health-related quality of life among persons with irritable bowel syndrome: a systematic review. Aliment Pharmacol Ther. 2002;16(6):1171-85. PMID 12030961 — cited by: quality-of-life-and-stigma.md
• Farndale R, et al. Long-term impact of irritable bowel syndrome: a qualitative study. Prim Health Care Res Dev. 2011;12(1):52-67. PMID 21426615 — cited by: quality-of-life-and-stigma.md
• Frank L, et al. Health-related quality of life associated with irritable bowel syndrome: comparison with other chronic diseases. Clin Ther. 2002;24(4):675-89; discussion 674. PMID 12017411 — cited by: quality-of-life-and-stigma.md
• Frändemark Å, et al. Work Productivity and Activity Impairment in Irritable Bowel Syndrome (IBS): A Multifaceted Problem. Am J Gastroenterol. 2018;113(10):1540-1549. PMID 30254230 — cited by: quality-of-life-and-stigma.md
• Goodoory VC, et al. Impact of Rome IV irritable bowel syndrome on work and activities of daily living. Aliment Pharmacol Ther. 2022;56(5):844-856. PMID 35794733 — cited by: overview.md, quality-of-life-and-stigma.md
• Goodoory VC, et al. Factors associated with lower disease-specific and generic health-related quality of life in Rome IV irritable bowel syndrome. Aliment Pharmacol Ther. 2023;57(3):323-334. PMID 36544055 — cited by: overview.md, quality-of-life-and-stigma.md
• Halpert A, et al. What patients know about irritable bowel syndrome (IBS) and what they would like to know. National Survey on Patient Educational Needs in IBS and development and validation of the Patient Educational Needs Questionnaire (PEQ). Am J Gastroenterol. 2007;102(9):1972-82. PMID 17488254 — cited by: quality-of-life-and-stigma.md
• Halpert A, et al. Irritable bowel syndrome patients' ideal expectations and recent experiences with healthcare providers: a national survey. Dig Dis Sci. 2010;55(2):375-83. PMID 19513835 — cited by: quality-of-life-and-stigma.md
• Halpert A, et al. Irritable bowel syndrome patients' perspectives on their relationships with healthcare providers. Scand J Gastroenterol. 2011;46(7-8):823-30. PMID 21561228 — cited by: quality-of-life-and-stigma.md
• Jakobsson Ung E, et al. How patients with long-term experience of living with irritable bowel syndrome manage illness in daily life: a qualitative study. Eur J Gastroenterol Hepatol. 2013;25(12):1478-83. PMID 24047860 — cited by: quality-of-life-and-stigma.md
• Manning LP, et al. Exploring the Experiences and Expectations of a Structured Low Fermentable Oligo-, Di-, Monosaccharide and Polyol Diet in People with Irritable Bowel Syndrome: A Qualitative Investigation. J Acad Nutr Diet. 2026; article 156437. PMID 42586418 — cited by: patient-voice/sources.md, patient-voice/themes.md
• Mohebbi Z, et al. Self-Perception of Iranian Patients during their life with Irritable Bowel Syndrome: A Qualitative Study. Electron Physician. 2017;9(12):5885-5893. PMID 29560138 — cited by: quality-of-life-and-stigma.md
• Parker CH, et al. The Role of Resilience in Irritable Bowel Syndrome, Other Chronic Gastrointestinal Conditions, and the General Population. Clin Gastroenterol Hepatol. 2021;19(12):2541-2550.e1. PMID 32835842 — cited by: quality-of-life-and-stigma.md
• Sherwin LB. Layperson's knowledge and perceptions of irritable bowel syndrome as potential barriers to care. J Adv Nurs. 2018;74(5):1199-1207. PMID 29319900 — cited by: quality-of-life-and-stigma.md, patient-voice/sources.md, patient-voice/themes.md
• Taft TH, et al. Stigmatization toward irritable bowel syndrome and inflammatory bowel disease in an online cohort. Neurogastroenterol Motil. 2017;29(2). PMID 27501483 — cited by: overview.md, quality-of-life-and-stigma.md
• Sun S, et al. Patients' perspectives on irritable bowel syndrome: a qualitative analysis based on social media in China. Qual Life Res. 2023;32(9):2561-2571. PMID 37093542 — cited by: patient-voice/sources.md, patient-voice/themes.md (retrieved but excluded from thematic synthesis under the no-social-media rule)

Alarm features, drug harms and safety

12 records.

• Corsetti M, et al. Targeting mu opioid receptors to modulate gastrointestinal function: what have we learnt so far from the studies in functional bowel disorders?. F1000Res. 2019;8. PMID 30863534 — cited by: red-flags-and-safety-concerns.md
• Deng Z, et al. Causality Between Irritable Bowel Syndrome and Suicide Attempt: A Mendelian Randomization Study. Brain Behav. 2025;15(5):e70513. PMID 40320944 — cited by: red-flags-and-safety-concerns.md
• Frazzoni L, et al. Clinical value of alarm features for colorectal cancer: a meta-analysis. Endoscopy. 2023;55(5):458-468. PMID 36241197 — cited by: red-flags-and-safety-concerns.md
• Fukudo S, et al. Centrally Mediated Disorders of Gastrointestinal Pain. Gastroenterology. 2026;170(6):1283-1302. PMID 41692277 — cited by: red-flags-and-safety-concerns.md
• Hughes PA, et al. Opioidergic effects on enteric and sensory nerves in the lower GI tract: basic mechanisms and clinical implications. Am J Physiol Gastrointest Liver Physiol. 2016;311(3):G501-13. PMID 27469369 — cited by: red-flags-and-safety-concerns.md
• Keefer L, et al. Centrally Mediated Disorders of Gastrointestinal Pain. Gastroenterology. 2016. PMID 27144628 — cited by: red-flags-and-safety-concerns.md
• Li H, et al. Associations Between Irritable Bowel Syndrome, Depression, Anxiety, and Suicidal Ideation: a Partial Least Squares Path Analysis. Psychiatr Q. 2026. PMID 42034841 — cited by: red-flags-and-safety-concerns.md
• Lin YM, et al. An opioid receptor-independent mechanism underlies motility dysfunction and visceral hyperalgesia in opioid-induced bowel dysfunction. Am J Physiol Gastrointest Liver Physiol. 2021;320(6):G1093-G1104. PMID 33908261 — cited by: red-flags-and-safety-concerns.md
• Longstreth GF, et al. Avoiding unnecessary surgery in irritable bowel syndrome. Gut. 2007;56(5):608-10. PMID 17440179 — cited by: red-flags-and-safety-concerns.md
• Miller V, et al. Suicidal ideation in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2004;2(12):1064-8. PMID 15625650 — cited by: overview.md, red-flags-and-safety-concerns.md
• Tong GX, et al. Diagnostic value of rectal bleeding in predicting colorectal cancer: a systematic review. Asian Pac J Cancer Prev. 2014;15(2):1015-21. PMID 24568444 — cited by: red-flags-and-safety-concerns.md
• Wileman V, et al. Development and preliminary evaluation of a suicidal risk assessment protocol in a randomised controlled trial using the Patient Health Questionnaire (PHQ-9). Trials. 2024;25(1):476. PMID 38997767 — cited by: red-flags-and-safety-concerns.md

Guidelines and consensus documents

20 PubMed records plus 2 institutional documents.

• NICE. Irritable bowel syndrome in adults: diagnosis and management (CG61). Published 2008; last updated 2017; surveillance reviewed 2025. https://www.nice.org.uk/guidance/cg61 (accessed 2026-09-02) — cited by: guidelines.md
• NICE. Chronic pain (primary and secondary) in over 16s (NG193). Published 2021. https://www.nice.org.uk/guidance/ng193 (accessed 2026-09-02) — cited by: guidelines.md
• Ford AC, et al. American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2018;113(Suppl 2):1-18. PMID 29950604 — cited by: guidelines/REGISTRY.md
• Barbara G, et al. Italian guidelines for the management of irritable bowel syndrome: Joint Consensus from the Italian Societies of: Gastroenterology and Endoscopy (SIGE), Neurogastroenterology and Motility (SINGEM), Hospital Gastroenterologists and Endoscopists (AIGO), Digestive Endoscopy (SIED), General Medicine (SIMG), Gastroenterology, Hepatology and Pediatric Nutrition (SIGENP) and Pediatrics (SIP). Dig Liver Dis. 2023;55(2):187-207. PMID 36517261 — cited by: guidelines.md
• Choi Y, et al. 2025 Seoul Consensus on Clinical Practice Guidelines for Irritable Bowel Syndrome. J Neurogastroenterol Motil. 2025;31(2):133-169. PMID 40205893 — cited by: guidelines.md
• Di Nardo G, et al. Italian guidelines for the management of irritable bowel syndrome in children and adolescents : Joint Consensus from the Italian Societies of: Gastroenterology, Hepatology and Pediatric Nutrition (SIGENP), Pediatrics (SIP), Gastroenterology and Endoscopy (SIGE) and Neurogastroenterology and Motility (SINGEM). Ital J Pediatr. 2024;50(1):51. PMID 38486305 — cited by: guidelines.md
• Fukudo S, et al. Evidence-based clinical practice guidelines for irritable bowel syndrome. J Gastroenterol. 2015;50(1):11-30. PMID 25500976 — cited by: guidelines.md
• Fukudo S, et al. Evidence-based clinical practice guidelines for irritable bowel syndrome 2020. J Gastroenterol. 2021;56(3):193-217. PMID 33538894 — cited by: guidelines.md
• Fukudo S, et al. Correction: Evidence-based clinical practice guidelines for irritable bowel syndrome 2020. J Gastroenterol. 2023;58(10):1019. PMID 37752291 — cited by: guidelines/REGISTRY.md
• Groen J, et al. ESPGHAN/NASPGHAN guidelines for treatment of irritable bowel syndrome and functional abdominal pain-not otherwise specified in children aged 4-18 years. J Pediatr Gastroenterol Nutr. 2025;81(2):442-471. PMID 40444524 — cited by: guidelines.md
• Gwee KA, et al. Second Asian Consensus on Irritable Bowel Syndrome. J Neurogastroenterol Motil. 2019;25(3):343-362. PMID 31327218 — cited by: guidelines.md
• Harkness EF, et al. GP perspectives of irritable bowel syndrome--an accepted illness, but management deviates from guidelines: a qualitative study. BMC Fam Pract. 2013;14:92. PMID 23805998 — cited by: guidelines.md
• Jones J, et al. British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome. Gut. 2000;47 Suppl 2:ii1-19. PMID 11053260 — cited by: guidelines/REGISTRY.md
• Kwon JG, et al. Guidelines for the treatment of irritable bowel syndrome. Korean J Gastroenterol. 2011;57(2):82-99. PMID 21350320 — cited by: guidelines/REGISTRY.md
• Layer P, et al. [Irritable bowel syndrome: German consensus guidelines on definition, pathophysiology and management]. Z Gastroenterol. 2011;49(2):237-93. PMID 21287438 — cited by: guidelines.md
• McKenzie YA, et al. British Dietetic Association evidence-based guidelines for the dietary management of irritable bowel syndrome in adults. J Hum Nutr Diet. 2012;25(3):260-74. PMID 22489905 — cited by: guidelines/REGISTRY.md
• Fass R, et al. Evidence- and consensus-based practice guidelines for the diagnosis of irritable bowel syndrome. Arch Intern Med. 2001;161(17):2081-8. PMID 11570936 — cited by: guidelines/REGISTRY.md
• Quigley EM, et al. World Gastroenterology Organisation Global Guidelines Irritable Bowel Syndrome: A Global Perspective Update September 2015. J Clin Gastroenterol. 2016;50(9):704-13. PMID 27623513 — cited by: guidelines.md
• Remes-Troche JM, et al. Pharmacologic treatment of irritable bowel syndrome. Position statement of the Asociación Mexicana de Gastroenterología, 2024. Rev Gastroenterol Mex (Engl Ed). 2025;90(1):77-110. PMID 40307155 — cited by: guidelines.md
• Sinopoulou V, et al. Efficacy of interventions for the treatment of irritable bowel syndrome, functional abdominal pain-not otherwise specified, and abdominal migraine in children: a systematic review and network meta-analysis. Lancet Child Adolesc Health. 2025;9(5):315-324. PMID 40246358 — cited by: guidelines.md
• Song KH, et al. Clinical Practice Guidelines for Irritable Bowel Syndrome in Korea, 2017 Revised Edition. J Neurogastroenterol Motil. 2018;24(2):197-215. PMID 29605976 — cited by: guidelines.md
• Spiller R, et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut. 2007;56(12):1770-98. PMID 17488783 — cited by: guidelines/REGISTRY.md

Clinical trials landscape

2 records.

• Liu J, et al. Efficacy and Safety of Transcutaneous Auricular Vagus Nerve Stimulation in Patients With Constipation-Predominant Irritable Bowel Syndrome: A Single-Center, Single-Blind, Randomized Controlled Trial. Am J Gastroenterol. 2024;120(9):2139-2153. PMID 39689011 — cited by: clinical-trials-landscape.md
• Veldman F, et al. Efficacy of vagus nerve stimulation in gastrointestinal disorders: a systematic review. Gastroenterol Rep (Oxf). 2025;13:goaf009. PMID 39867596 — cited by: clinical-trials-landscape.md

---

Total: 377 PubMed records across 20 wiki pages and the literature layer, plus two NICE institutional documents cited by official URL. Section counts are given under each heading. Landmark papers with dedicated deep notes are in notes/; guideline documents are catalogued with status and supersession chains in guidelines/REGISTRY.md; quantitative figures with their populations and methods are in statistics/STATISTICS.md.